Thymidine Phosphorylase Inhibitors

Anti-Angiogenesis Drug Discovery and Development

Volume: 1

DOI: 10.2174/978160805162511101010116
eISBN: 978-1-60805-162-5, 2011
ISBN: 978-1-60805-648-4
ISSN: 2452-3240 (Print)
ISSN: 2210-268X (Online)

Indexed in: Scopus, EBSCO, Ulrich's Periodicals Directory

The inhibition of angiogenesis is an effective mechanism of slowing down tumor growth and malignancies. The process of induction or pro-angiogenesis is highly desirable for the treatment of ...

[view complete introduction]

US $
	15

*(Excluding Mailing and Handling)

Back

Thymidine Phosphorylase Inhibitors

Pp. 116-147 (32)

Radim Nencka

Abstract

Thymidine phosphorylase (TP) is an enzyme that acts as a proangiogenic factor. Overexpression of the enzyme was observed in various solid tumors and several chronic inflammatory diseases, where it was correlated with level of angiogenesis and elevated progression of the disease. TP inhibitors are compounds designed to interfere with the processes connected with catalytic function of this enzyme including TP-mediated angiogenesis and the degradation of important antiviral and anticancer drugs. This chapter comprehensively reviews the hitherto known TP inhibitors with further insight into their potential applications in the clinical practices.

Keywords:

Thymidine phosphorylase, angiogenesis, platelet-derived endothelial cell growth factor, gliostatin, cancer chemotherapy, thymidine phosphorylase inhibitors.

Affiliation:

Gilead Sciences & IOCB Research Centre, Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic, Centre for New Antivirals and Antineoplastics (IOCB), Flemingovo nam.